Uvax Bio, LLC, a privately held, preclinical-stage vaccine company, today announced that its HIV vaccine candidates have shown significant improvement in immune response compared with current vaccine strategies, according to results from preclinical studies described in a paper published in Nature Communications titled, “Single-component multilayered self-assembling protein nanoparticles presenting glycan-trimmed uncleaved prefusion optimized envelope trimers as HIV-1 vaccine candidates.”